Innovations and Patent Trends in the Development of USFDA Approved Protein Kinase Inhibitors in the Last Two Decades

• Váldodahkkit: Mohd. Imran (Dahkki), Syed Mohammed Basheeruddin Asdaq (Dahkki), Shah Alam Khan (Dahkki), Dhanalekshmi Unnikrishnan Meenakshi (Dahkki), Abdulhakeem S. Alamri (Dahkki), Walaa F. Alsanie (Dahkki), Majid Alhomrani (Dahkki), Yahya Mohzari (Dahkki), Ahmed Alrashed (Dahkki), Mohammed AlMotairi (Dahkki), Eman H. Alkhaldi (Dahkki), Abeer K. Alorabi (Dahkki), Ahmed Subeh Alshrari (Dahkki), Mohammad Tauseef (Dahkki), Abida (Dahkki), Saleh I. Alaqel (Dahkki), Ozair Alam (Dahkki), Md. Afroz Bakht (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: MDPI AG, 2021-07-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Protein kinase inhibitors (PKIs) are important therapeutic agents. As of 31 May 2021, the United States Food and Drug Administration (USFDA) has approved 70 PKIs. Most of the PKIs are employed to treat cancer and inflammatory diseases. Imatinib was the first PKI approved by USFDA in 2001. This revie...